To address this critical knowledge gap, this study employs a rigorous multi-omics data analysis framework using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts to investigate FZD2’s expression patterns, prognostic value, immune microenvironment correlations, and drug sensitivity across pan-cancers. This evidence concerns the gene FZD2 and cancer.